Market Samachar
Home  ›  GLOBAL
Language Englishతెలుగుहिन्दीதமிழ்मराठीবাংলাಕನ್ನಡ
CNBC · GLOBAL ·

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial - cnbc.com

As reported by CNBC
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
▸ MARKET SAMACHAR VIEW
NEUTRAL
Read full article on CNBC ↗

Market Samachar is a news aggregator. This article was originally published by CNBC. Tap the button above to read the full story on their site.

🔥 Hot Now
Top stories across markets in the last hour

More from Market Samachar